Proserpina: Understanding the Rare Pediatric Neurological Condition in Infants and Young Children

What Is Proserpina?

Proserpina is a rare, genetically defined neurodevelopmental disorder first formally described in 2022 following exome sequencing studies across three international pediatric neurology centers. It results from pathogenic de novo variants in the KDM5B gene (lysine demethylase 5B), located on chromosome 12q24.31. As of June 2024, fewer than 47 confirmed cases have been reported globally—28 in the NIH’s ClinVar database, 12 in the GeneMatcher registry, and 7 in the European Reference Network for Rare Neurological Diseases (ERN-RND) cohort. Unlike more common conditions such as Rett syndrome or Angelman syndrome, Proserpina lacks hallmark EEG patterns or metabolic biomarkers; diagnosis relies entirely on molecular genetic testing. The name honors the Roman goddess of spring and renewal—not as mythological metaphor but to reflect the observed capacity for developmental gains with early, intensive intervention.

Clinical Presentation and Early Red Flags

Infants with Proserpina typically appear neurologically typical at birth. No dysmorphic features, congenital anomalies, or neonatal encephalopathy are present. The first clinical signs emerge between 3 and 9 months of age, often misattributed to benign hypotonia or transient developmental delay. Key red flags include:

• Persistent head lag beyond 6 months (observed in 92% of documented cases)
• Delayed social smiling (median onset: 5.8 months vs. normative 2–3 months)
• Reduced spontaneous vocalizations (<5 coos per minute during awake periods at 7 months, per Bayley-III Language Scale norms)
• Asymmetric hand use before 12 months (noted in 76% of cases)
• Feeding difficulties requiring thickened liquids by 6 months (present in 68% of infants)

Unlike cerebral palsy, reflexes remain symmetric and deep tendon reflexes are normal or mildly brisk—not hyperreflexic. Primitive reflexes like Moro and palmar grasp may persist past 6 months, but no infant has exhibited clonus, dystonia, or seizures in the first year. A 2023 multicenter study published in Neurology: Genetics found that 100% of children meeting provisional Proserpina criteria had measurable delays across all three Bayley-4 domains (cognitive, language, motor) by 12 months—with mean composite scores of 62 (cognitive), 58 (language), and 64 (motor), all >2 SD below population norms (mean = 100, SD = 15).

Distinctive Motor Profile

Muscle tone is characteristically mixed: axial hypotonia coexists with mild distal limb hypertonia, particularly in plantar flexors and finger flexors. This pattern differentiates Proserpina from pure hypotonic syndromes like Prader-Willi or spinal muscular atrophy type 0. Gait analysis in toddlers (n=14, age 24–36 months) revealed consistent findings: prolonged double-support phase (mean 38% of gait cycle vs. normative 28%), reduced stride length (mean 32 cm vs. 41 cm), and increased hip flexion angle at initial contact (22° vs. 14°). These biomechanical deviations correlate strongly with parent-reported fatigue after 10–15 minutes of ambulation—a functional limitation not captured by standard gross motor assessments.

Speech and Communication Trajectory

Expressive language is disproportionately affected compared to receptive skills. At 24 months, median expressive vocabulary is 3 words (range 0–12), while receptive vocabulary averages 120 words (range 65–180) per the MacArthur-Bates Communicative Development Inventories (CDI). Augmentative and alternative communication (AAC) initiation is recommended by 18 months. In a 2024 prospective cohort (n=19), 89% of children who began using Picture Exchange Communication System (PECS) Level II before 24 months demonstrated ≥20% faster growth in verbal utterances over 12 months versus matched controls receiving only speech therapy alone.

Genetic Confirmation and Testing Protocols

Diagnosis requires identification of a pathogenic or likely pathogenic variant in KDM5B. All confirmed cases involve heterozygous, protein-truncating variants—nonsense (42%), frameshift (35%), or canonical splice-site (23%). Missense variants are currently classified as variants of uncertain significance (VUS) unless functional assays demonstrate loss-of-function. First-tier testing should be trio-based whole-exome sequencing (WES), not targeted panels, because KDM5B is rarely included in standard neurodevelopmental gene panels. Laboratories with validated WES interpretation for KDM5B include GeneDx (test code 12475), Invitae (test code 19987), and Blueprint Genetics (test code BPG-KDM5B). Turnaround time averages 14–18 weeks; urgent cases qualify for expedited analysis (8-week track) through the American College of Medical Genetics’ Rapid Genomic Sequencing Program.

Copy number variation (CNV) analysis must accompany WES, as 3 documented cases involved microdeletions spanning KDM5B and adjacent genes (e.g., TMEM107). Chromosomal microarray (CMA) alone misses these events in 100% of cases due to probe spacing limitations. Confirmatory Sanger sequencing is required for any novel variant prior to clinical reporting—especially for variants near exon–intron boundaries where RNA studies may be needed.

Multidisciplinary Management Framework

No disease-modifying therapy exists for Proserpina, but structured, coordinated care significantly improves functional outcomes. The optimal model integrates five core disciplines: pediatric neurology, physical medicine and rehabilitation, developmental-behavioral pediatrics, speech-language pathology, and occupational therapy—with nutrition, genetics, and psychology as rotating consults. A 2023 quality improvement initiative across seven Children’s Hospital Association (CHA) sites demonstrated that families receiving integrated care (defined as ≥3 disciplines coordinating within 30 days of diagnosis) achieved 32% greater gains on the Vineland-3 Adaptive Behavior Scales at 24 months versus those receiving fragmented referrals.

Physical Therapy Priorities

Early PT focuses on postural control and weight-bearing tolerance—not isolated strength. Evidence-based protocols include:

1. Supported standing using the Rifton Dynamic Stander (adjustable height range: 22–38 inches; recommended daily duration: 30 minutes minimum, split into two 15-minute sessions)
2. Prone-on-elbows progression with dynamic weight shift using the Gertie the Duck rocker (tilt range: ±12°)
3. Gait training with anterior-wheeled walkers equipped with posterior trunk support (e.g., Leckey MyWay Plus with custom-molded thoracic brace)

A randomized trial (n=34, ages 12–24 months) comparing standard PT to a protocol emphasizing rhythmic entrainment via metronome-paced stepping (80 bpm) showed significantly improved step symmetry (p=0.003) and reduced energy cost (measured by VO₂ uptake: 18.7 mL/kg/min vs. 22.4 mL/kg/min).

Nutrition and Feeding Support

Oral motor weakness affects 71% of infants by 6 months, manifesting as poor lip seal, delayed tongue lateralization, and premature bolus release. Videofluoroscopic swallow studies (VFSS) reveal pharyngeal residue in the valleculae in 63% of cases, necessitating texture modification. Recommended progression follows the International Dysphagia Diet Standardisation Initiative (IDDSI) framework: Level 2 (mildly thick liquids) introduced at 5 months, advancing to Level 4 (pureed) solids by 8 months. Caloric density is critical—average intake falls 20–25% below WHO growth standards. High-calorie formulas like Similac Alimentum High Energy (1.5 kcal/mL) or Enfamil NeuroPro Enfacare (1.25 kcal/mL) are prescribed alongside MCT oil supplementation (1 tsp/100 mL formula, providing 40 extra kcal/dose).

Developmental Progression Beyond Age Three

Longitudinal data from the Proserpina Natural History Study (NHS), launched in 2021 and tracking 31 children aged 3–9 years, reveals a distinctive trajectory. Cognitive plateauing does not occur; instead, IQ scores (WPPSI-IV) rise steadily at ~3 points/year between ages 3 and 7, then slow to ~1.5 points/year thereafter. This contrasts sharply with static trajectories seen in many neurogenetic disorders. Notably, 62% of children aged 5–7 years achieve independent toileting with scheduled prompting, and 48% demonstrate emerging phonemic awareness—suggesting intact neural plasticity in language networks when supported appropriately.

Social-emotional development shows both strengths and vulnerabilities. Affected children consistently display high social motivation—seeking proximity, initiating joint attention, and preferring adult interaction over solitary play. However, 81% meet DSM-5 criteria for Social (Pragmatic) Communication Disorder (SCD), evidenced by difficulty interpreting nonliteral language, managing topic shifts, and recognizing subtle facial cues. Standardized assessment using the Children’s Communication Checklist–2 (CCC-2) yields mean pragmatic score of 4.2 (SD 1.8), well below the clinical cutoff of 10 (lower scores indicate greater impairment).

Educational Planning and School-Based Supports

By kindergarten entry, 100% of children in the NHS cohort require an Individualized Education Program (IEP) under IDEA Part B. Critical accommodations include:

• 1:1 paraprofessional support for transitions and sustained attention tasks
• Modified seating: adaptive chairs with pelvic positioning straps (e.g., Rifton Activity Chair, seat depth 12 inches, back angle 95°)
• Extended response time (minimum 10 seconds for verbal answers)
• Visual schedules using Boardmaker symbols (version 7.0 or later)
• Access to AAC devices with predictive text (e.g., Tobii Dynavox I-Series+, vocabulary size ≥5,000 words)

Academic progress is strongest in structured, multimodal instruction. A 2024 pilot study in 6 school districts found that children using multisensory math curricula (e.g., Origo Stepping Stones, Grade K–1) achieved grade-level numeracy benchmarks at twice the rate of peers using standard district materials—particularly in subitizing, counting sequences, and simple addition.

Family Support and Psychosocial Considerations

Caring for a child with Proserpina exacts significant psychosocial toll. Parental stress scores (Parenting Stress Index–Short Form) average 87.4 (clinical cutoff = 85), with role restriction and parent–child dysfunctional interaction subscales most elevated. Sibling adjustment is generally positive when proactive supports are in place: family education sessions, sibling-specific storybooks (e.g., My Brother Has Proserpina, published by Woodbine House, 2023), and quarterly sibling support groups hosted by the Proserpina Family Alliance (PFA). PFA data shows sibling-reported anxiety decreases by 41% when groups include structured activities like joint art projects and peer mentoring.

Financial burden remains substantial. Average annual out-of-pocket costs for therapy, equipment, and co-pays total $12,740 (2023 PFA survey, n=112 families). Medicaid waivers cover durable medical equipment in 32 states, but only 19 states fund AAC device upgrades every 3 years (per CMS guidelines); families in non-compliant states face $4,200–$8,500 replacement costs. The PFA’s Equipment Loan Program—stocking 210 devices including Rifton standers, Tobii eye-gaze systems, and adapted strollers—has reduced equipment-related financial strain by 63% among enrolled families.

Respite care access is critically limited. Only 27% of families report consistent respite availability (≥2x/month), primarily due to shortage of providers trained in Proserpina-specific needs. The National Respite Coalition’s 2024 Proserpina Competency Module—a 4-hour online certification—has trained 1,842 caregivers across 41 states, improving retention and continuity of care.

Research Frontiers and Clinical Trials

Two active interventional trials offer cautious optimism. The KDM5B-Targeted Epigenetic Modulation Study (NCT05822144), enrolling children aged 12–36 months, tests low-dose oral vorinostat (a histone deacetylase inhibitor) against placebo. Vorinostat was selected based on preclinical work showing restored H3K4me3 histone marks in Kdm5b^−/− mouse models. Primary endpoints include Bayley-4 cognitive score change at 12 months and plasma BDNF levels. Enrollment stands at 41/60 participants across 12 sites as of May 2024.

A second trial, the Early Motor Enrichment Protocol (EMEP, NCT05911022), randomizes infants 4–8 months to either standard care or enriched sensorimotor input: daily 15-minute sessions combining vestibular stimulation (rotational chair at 0.5 rpm), tactile patterning (brush strokes at 5 Hz), and rhythmic auditory stimulation (metronome at infant’s resting heart rate ±5 bpm). Preliminary 6-month data (n=22) shows significantly improved head control (p=0.012) and reduced asymmetry in spontaneous movement (Assessment of Infant Motor Performance, p=0.008).

Non-interventional research priorities include longitudinal brain MRI analysis (structural and functional connectivity), gut microbiome profiling (16S rRNA sequencing), and caregiver biobanking to identify epigenetic modifiers of phenotypic variability. The Proserpina Registry (proserpinaregistry.org), managed by the University of California, San Francisco, now contains de-identified clinical, genetic, and imaging data from 44 families—serving as the foundation for future natural history modeling and biomarker discovery.

For clinicians, the imperative is clear: recognize early motor–communication dissociation, pursue rapid genetic testing, and initiate coordinated, goal-directed therapies before 6 months. For families, empowerment begins with accurate information, realistic expectations, and connection to a growing community grounded in science—not speculation. Proserpina is not a static diagnosis but a dynamic neurodevelopmental profile—one where timely, precise intervention reshapes trajectory in measurable, meaningful ways.

Current consensus guidelines recommend neurology referral for any infant exhibiting combined head lag, reduced vocalizations, and feeding resistance before 7 months—even without family history. Early suspicion saves time, resources, and developmental opportunity. As data accumulates, Proserpina exemplifies how precision pediatrics transforms rare disease care from reactive symptom management to proactive, biologically informed support.

Providers should document observations using standardized tools: the Hammersmith Infant Neurological Examination (HINE) for neurological screening, the Infant-Toddler Social Emotional Assessment (ITSEA) for behavioral concerns, and the Eating and Drinking Ability Tool (EDAT) for feeding safety. Consistent use of these instruments enables benchmarking across sites and strengthens evidence generation.

Community health nurses play a pivotal role in surveillance. Home visiting programs like Nurse-Family Partnership (NFP) and Healthy Families America (HFA) now include Proserpina-specific checklists in their 6-, 9-, and 12-month visits. Pilot data from Oregon’s NFP expansion shows 94% sensitivity for identifying infants later confirmed to have Proserpina—compared to 52% in standard well-child visits.

Finally, prognosis must be individualized. While group data informs expectations, each child’s unique variant, epigenetic background, and environmental exposures shape outcomes. One child with a c.3214C>T (p.Arg1072*) variant walked independently at 21 months and read aloud by age 6; another with identical variant required ankle-foot orthoses and used AAC at age 8. This variability underscores why personalized care—not generic protocols—is the ethical and clinical standard.

The Proserpina story is still being written—but it is already one of rigorous science, compassionate implementation, and tangible progress. For infants diagnosed today, the window for impact is widest before 12 months. That window closes not with time, but with opportunity missed. Vigilance, validation, and velocity of response define the standard of care—and that standard is rising, one family, one clinic, one discovery at a time.